Of note, the TP53 variants maintained a high VAF (∼40%) in plasma during and after treatment despite early clearance (EMR) of the IGLL5 variants and sustained remission from DLBCL (Figure 4C). This evidence concerns the gene TP53 and diffuse large B-cell lymphoma.